Licochalcone D

Research use only, not for human use.

Licochalcone D may be a potential drug for human melanoma treatment by inhibiting proliferation, inducing apoptosis via the mitochondrial pathway and blocking cell migration and invasion.

Licochalcone D may be a potential drug for human melanoma treatment by inhibiting proliferation, inducing apoptosis via the mitochondrial pathway and blocking cell migration and invasion. Licochalcone D has cardioprotective potential against myocardial ischemia/reperfusion injury in langendorff-perfused rat hearts. Licochalcone D has anti-inflammatory activity, it shows suppression ability of nitric oxide (NO) production. Licochalcone D has anti-allergic activity, it suppresses degranulation by decreasing the intracellular Ca2+ level and tyrosine phosphorylation of ERK in RBL-2H3 cells.

Western Blot Analysis Cell Line:RAW264.7 cells Concentration:10 μM Incubation Time:1 h or 24 h (iNOS), following LPS stimulation (1 μg/mL) for 30 min Result:Inhibited the phosphorylation of NF-κB at serine 276 but not at serine 536.Inhibited the LPS-induced expression of TNFα mRNA and MCP-1 mRNA.Strongly inhibited the expression of iNOS.Cell Viability Assay Cell Line:A375 cells or SK-MEL-5 Concentration:0, 1, 2.5, 5, 15, 30, 45, 60, 75 and 90 μM (A375) or 0, 20, 40, 60 and 80 μM (SK-MEL-5)Incubation Time:24 h Result:Inhibited the proliferation of A375 and SK-MEL-5 in a concentration dependent manner.Apoptosis Analysis Cell Line:A375 Concentration:0, 30, 60 and 90 μM Incubation Time:24 h Result:Cells exhibited obvious apoptotic characteristics after the treatment.RT-PCR Cell Line:A375 Concentration:0, 30, 60 and 90 μM Incubation Time:24 h Result:Downregulated the mRNA level of Bcl-2 and upregulated the mRNA levels of caspase-3, caspase-9 and Bax.Cell Invasion Assay Cell Line:A375 Concentration:25 μM Incubation Time:24 h Result:Significantly suppressed cell invasion.Cell Migration Assay Cell Line:A375 Concentration:25 μM Incubation Time:24 h Result:Significantly suppressed cell migration in the A375 cells.

Animal Model:C57BL/6 mice, B16F0 tumor modelDosage:25 and 50 mg/kg Administration:Intragastric administration, daily for a week Result:Obviously lowered the tumor growth rates, the tumor growth inhibition rates were calculated to be 32.0 and 54.1% at 25 and 50 mg/kg, respectively.

Licochalcone D | Licochalcone-D

MAPK/ERK Signaling

p38 MAPK

ERK phosphorylation

——

——

144506-15-0

354.4

C21H22O5

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (352.71 mM)

COc1c(O)c(O)ccc1\C=C\C(=O)c1ccc(O)c(CC=C(C)C)c1

(E)-3-(3,4-Dihydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]prop-2-en-1-one

(-20℃)

With Ice Pack

≥ 2 years